Haleon plc (NYSE:HLN) Shares Purchased by Huntington National Bank

Huntington National Bank lifted its holdings in Haleon plc (NYSE:HLN) by 7.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,084 shares of the company’s stock after acquiring an additional 2,568 shares during the period. Huntington National Bank’s holdings in Haleon were worth $414,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Fortitude Family Office LLC acquired a new stake in Haleon in the 3rd quarter valued at $28,000. Cultivar Capital Inc. purchased a new stake in shares of Haleon in the second quarter worth about $40,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Haleon in the first quarter valued at about $43,000. Hexagon Capital Partners LLC raised its holdings in shares of Haleon by 66.6% during the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after buying an additional 2,677 shares during the period. Finally, BOKF NA lifted its position in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after acquiring an additional 2,842 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on HLN shares. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley boosted their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Berenberg Bank assumed coverage on shares of Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating for the company. Finally, The Goldman Sachs Group cut Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Haleon currently has a consensus rating of “Buy” and a consensus price target of $10.95.

Haleon Stock Up 0.9 %

Shares of NYSE:HLN opened at $9.39 on Friday. The firm has a market cap of $42.51 billion, a PE ratio of 27.62, a price-to-earnings-growth ratio of 2.79 and a beta of 0.30. The company has a fifty day simple moving average of $10.10 and a 200 day simple moving average of $9.34. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.